Skip to main content
Clinical Trials/NCT05324930
NCT05324930
Completed
Not Applicable

Evaluating the Effectiveness of Collagen Matrix Dressing on Neuropathic Diabetic Foot Ulcer in T2DM Patients: a Randomised Control Trial

Corporacion Parc Tauli1 site in 1 country180 target enrollmentDecember 2, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetic Foot Ulcer Neuropathic
Sponsor
Corporacion Parc Tauli
Enrollment
180
Locations
1
Primary Endpoint
Change in DFU size
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Diabetic foot ulcers (DFU) are challenging to treat with complicated healing processes and require advanced wound care. Piscean collagen has the potential to promote the regenerative process while remaining cost-effective and with minimal side effects. In this study, the efficacy of a piscean collagen matrix dressing was compared with a standard dressing of saline-moistened gauze for wound healing in patients with neuropathic DFU.

This is a double-blinded, randomised clinical trial.

Detailed Description

Diabetic foot ulcers (DFU) are challenging to treat with complicated healing processes and require advanced wound care. Piscean collagen has the potential to promote the regenerative process while remaining cost-effective and with minimal side effects. In this study, the efficacy of a piscean collagen matrix dressing was compared with a standard dressing of saline-moistened gauze for wound healing in patients with neuropathic DFU. This is a double-blinded, randomised clinical trial. After conventional therapy consisting of debridement, infection control and offloading, patients were randomly allocated to receive either a piscean matrix dressing (the study group) or a saline-moistened gauze dressing (control group) for wound care. The reduction in DFU size and the number of patients with complete healing were measured throughout the treatment and in follow-up.

Registry
clinicaltrials.gov
Start Date
December 2, 2021
End Date
September 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Corporacion Parc Tauli
Responsible Party
Principal Investigator
Principal Investigator

Dr Zainab Khan

Chief Resident

Corporacion Parc Tauli

Eligibility Criteria

Inclusion Criteria

  • patients with neuropathic DFUs at Grades I or II for a period of at least 12 weeks, based on the Wagner classification;
  • be able to understand simple instructions and provided voluntary, signed informed consent.

Exclusion Criteria

  • active infection which might lead to hospitalisation, gangrene,
  • systemic inflammatory or autoimmune disease
  • renal failure
  • presence of ischaemia or osteomyelitis

Outcomes

Primary Outcomes

Change in DFU size

Time Frame: 3 months

change in DFU size using the manual planimetric method

Secondary Outcomes

  • Complete wound healing(3 months)

Study Sites (1)

Loading locations...

Similar Trials